Status:
COMPLETED
Effectiveness Study Low-Dose Naltrexone Versus ARV's for HIV+
Lead Sponsor:
The Ojai Foundation
Conditions:
HIV Seropositivity
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
In the vast majority of those infected with HIV virus who are untreated, there is deterioration in immune health over a period of months or years inevitably leading to full-blown AIDS and demise. Trea...
Detailed Description
The LDN (low-dose naltrexone) vs ARV (anti-retroviral drugs) Effectiveness Study in Mali sponsored by The Ojai Foundation in California-USA is a clinical research study endorsed and approved by the Ma...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- HIV-1 infected
- CD4 count over 350 (arm 1/group 1)
- CD4 count over 200 and on ARV's (arms 2,3/groups 2,3)
- Age between 18 \& 60
- Males or females
- Exclusion criteria:
- HIV-1 seronegative
- HIV-2 infected
- CD4 count lower than 200
- patients under age 18
- Those refusing to be in study
- Pregnant or breast-feeding women
- Patients under immuno-suppressor therapy
- Those with renal or hepatic dysfunction
- Malaria or tuberculosis
Exclusion
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2010
Estimated Enrollment :
171 Patients enrolled
Trial Details
Trial ID
NCT01174914
Start Date
March 1 2008
End Date
March 1 2010
Last Update
August 4 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of Point G
Bamako, Mali, BP0 Box 333